The drugs still work.
The tumors stop responding.
We design peptides to restore the tumor’s response.
AecorBio is an IND-enabling peptide therapeutics company. Our orally active peptides normalize the dysregulated gene expressions that drive treatment resistance, restoring the effectiveness of standard-of-care medicines across oncology, immunology and neurology.
REGULATORY STAGE
Favourable pre-IND response received for FIH Phase 1b in metastatic castration-resistant prostate cancer (mCRPC) patients
ORAL PEPTIDE DRUG
A co-treatment, not a replacement for standard of care (SOC)
Lead Drug Candidate
A first-in-class oral peptide drug that targets the iron dysregulation behind treatment resistance in prostate cancer.
Our lead peptide normalizes the dysregulated prostate tumor labile iron pool — a validated but previously undruggable resistance mechanism — restoring the efficacy of the standard-of-care (SOC) androgen receptor pathway inhibitors (ARPI) for mCRPC patients.
Two-Phase Market Entry for Prostate Cancer Treatment
MONTHS FROM START OF ARPI
TODAY
Standard of care alone
PUBLISHED OUTCOMES
0122436 mo
Months of ARPI response. Resistance emerges at 15–25 months; varies by population.
PHASE 1
Add drug product after resistance
TARGET PROFILE
0122436 mo
Intended effect: the same ARPI works again, extending time on effective treatment.
Preclinical basis: 66% tumor reduction in a resistant model where the ARPI alone had no effect.
PHASE 2
Add drug product from the start
TARGET PROFILE
0122436 mo
Intended effect: the response is deepened and resistance is delayed.
Preclinical basis: 98% tumor reduction when added to a treatment that was still working.
Dashed bars: the expected effect of our lead drug product. All efficacy and safety data described are from preclinical (in vitro and animal) studies.
Mode of Action
The Iron Gene Dysregulation Story
Androgen receptor pathway inhibitor (ARPI)-resistant prostate tumors accumulate toxic free iron, driven by dysregulation of the iron master regulatory gene — IREB2 (Iron Responsive Element Binding Protein 2).
Our lead drug product normalizes IREB2 expression to reduce free iron and successfully restore ARPI-mediated tumor control.
Our lead drug product normalizes IREB2 expression to reduce free iron and successfully restore ARPI-mediated tumor control.
Our drug product normalizes IREB2
Normalizing the master gene addresses all three downstream genes (TFRC, FTH1, FPN) together, and the labile iron pool returns to normal.
Overcoming resistance safely
This targeted approach clears the excess free iron the tumor depends on to escape ARPI treatment—doing so without toxicity or disruption to systemic iron homeostasis.
Novel Formulation
Peptide drugs are usually injected because gastric acid and digestive enzymes destroy them.
Our drug product is a novel oral formulation designed to survive gastric digestion.
The lead peptide is dispersed in polymerized alpha-lipoic acid (pALA) which is chemically stable in the stomach.
This biocompatible matrix completely depolymerizes only in the small intestine, releasing the peptide for systemic absorption.
This biocompatible matrix completely depolymerizes only in the small intestine, releasing the peptide for systemic absorption.
Clinical Development
From pre-IND to first patient in mCRPC
The oral capsule is the dosage form in our IND-enabling toxicology studies, and the intended form for the first-in-human Phase 1b in mCRPC patients.
REGULATORY
Pre-IND
Written response received; feedback supportive
MATERIAL
First GMP drug substance produced
Release method and specifications validated
PROTOCOL
Phase 1b designed for Optimal Biological Dose
In line with current regulatory guidance
[RECEIVED]
Pre-IND Feedback
[IN PROGRESS]
GLP Toxicology & Safety Studies
Ongoing.
[IN PROGRESS]
CMC & GMP Drug Product Manufacture
Drug substance and release profiles ongoing.
[UPCOMING]
Formal IND Submission
Compilation of Modules 1–5.
[UPCOMING]
Phase 1b First Patient In
Open-label study after ARPI progression.
Market
A sequential indication strategy — no approved therapy reverses ARPI resistance in any of these markets.
Our ARPI-combination mechanism opens three addressable markets in sequence, each mapped to the clinical plan: a first indication in metastatic disease, an earlier-line label expansion, and a pipeline indication that shares the same mechanism.
PHASE 1b · FIRST INDICATION
mCRPC
~$6.8B
Metastatic castration-resistant prostate cancer on or after an ARPI — the initial clinical indication and fastest path to a signal.
DelveInsight, 2023 · 7MM
+
PHASE 2–3 · LABEL EXPANSION
nmCRPC (locally progressive)
~$8.3B
Non-metastatic (M0) CRPC, where ARPIs are already standard of care — an earlier line with longer treatment duration.
Research Nester, 2025 · global
+
PIPELINE · ADJACENT INDICATION
Platinum-resistant ovarian
~$1.5B
The same labile iron pool / IREB2 mechanism in a separate indication — roughly 60,000 cases per year across the 7MM.
DelveInsight, 2021 · 7MM
≈$15B
TODAY
→
>$22B
BY 2030
Combined addressable market — Prostate CRPC (mCRPC + nmCRPC) grows from $13.0B to $21.4B by 2030 at 8.7% CAGR (Grand View Research), plus a ~$1.5B adjacent ovarian opportunity.
A bottom-up build (addressable patients × ARPI-combination share × annual net price) lands at ~$11B US and ~$21B global serviceable market.
A bottom-up build (addressable patients × ARPI-combination share × annual net price) lands at ~$11B US and ~$21B global serviceable market.
INTELLECTUAL PROPERTY
Composition of matter, methods of use, target and mechanism, and formulation — filed internationally.
Sources: Grand View Research (CRPC, global); DelveInsight (mCRPC and platinum-resistant ovarian, 7MM); Research Nester (nmCRPC). Geographies as labeled. Figures are third-party market estimates that vary by methodology and are provided for context only — not a forecast. Our lead drug product is investigational and has not been approved by the FDA.
Oncology franchise
The Oncology Franchise
One IND-enabling dossier unlocks a multi-cancer franchise.
In every cancer where iron dysregulation is a documented driver of resistance to standard of care, the IND-enabling dossier carries over unchanged: no new molecule, no new toxicology, no new manufacturing. Preclinical efficacy is the only new requirement, and once Phase 1b establishes human safety in mCRPC patients, each added indication is designed to move rapidly into Phase 2 on that same safety foundation.
One IND-enabling dossier supports the oncology franchise.
Drug substance · Drug product · Nonclinical safety · CMC & manufacturing
LEAD · IND-STAGE
Prostate (mCRPC)
Drug that stops working: ARPIs
Survival after resistance: ~9–16 mo
Survival after resistance: ~9–16 mo
PRECLINICAL
Ovarian (PROC)
Drug that stops working: Platinum chemotherapy
Survival after resistance: ~11–17 mo
Survival after resistance: ~11–17 mo
HYPOTHESIS
Endometrial
Drug that stops working: Progestins / endocrine
Survival after resistance: ~7–13 mo
Survival after resistance: ~7–13 mo
HYPOTHESIS
Breast (HR+)
Drug that stops working: Endocrine + CDK4/6
Survival after resistance: ~16–30 mo
Survival after resistance: ~16–30 mo
PUBLICATIONS
FTH1 modulation in vivo (Cancer Biol Ther, 2025) · Small peptides altering FTH1/TFRC in prostate cancer models (Int J Mol Sci, 2023) · Marine-derived oligopeptides with AR inhibition (ASCO / J Clin Oncol, 2023) · Peptide potentiation of bicalutamide via iron homeostasis (Mar Drugs, 2022)
The platform
Novel Discovery Platform
AecorBio first validates a clinically viable pharmacodynamic biomarker by confirming gene expression dysregulation in accessible patient tissue. Peptide motifs active on that target are then discovered from large natural libraries generated by targeted proteome hydrolysis. Our mCRPC co-treatment program is the first to complete this discovery-to-clinical pipeline.
TARGET VALIDATION (1–2) → PEPTIDE LEAD DISCOVERY (3–5)
1. Map the expression shift
Repeat-dose the standard of care and read the transcriptional shift
2. Confirm it in patients
Observational study in accessible patient tissue
3. Targeted hydrolysis
Proteome sources cleaved to yield thousands of natural peptides
4. Screen for Normalization
Ranked by transcriptional correction of the validated target gene
5. Optimize Lead Peptide
Analogue synthesis to an IP-protected clinical molecule
WHAT MAKES IT DIFFERENT
Human-validated targets
Confirmed in patient tissue before any medicinal chemistry begins
Natural peptide libraries
Targeted hydrolysis of proteome sources, not combinatorial synthesis
Parallel screening
Hundreds of libraries read out at once on expression, compressing discovery
Peptide tolerability
Leads degrade to amino acids; no toxicity ceiling reached in the lead program
Beyond Oncology
Treatment resistance driven by dysregulated gene expression is not limited to cancer.
For eosinophilic asthma and restless legs syndrome, current standards of care lose efficacy as the expression of a critical target gene becomes dysregulated. Our discovery-stage platform identifies novel peptides designed to directly target and correct this underlying gene dysregulation.
IMMUNOLOGY
PRECLINICAL
Targeting steroid-resistant eosinophilic asthma & eosinophilic esophagitis (EoE)
Pre-clinical Lead Lipopeptide Compound
STANDARD OF CAREInhaled and oral corticosteroids
RESISTANCE MECHANISMElevated IL-5 gene expression blocks steroid-driven eosinophil apoptosis
WHAT WE NORMALIZEIL-5 gene expression normalized — steroid efficacy restored
NEUROLOGY
LEAD OPTIMIZATION
Targeting augmentation syndrome in restless legs syndrome (RLS), including RLS in Parkinson’s disease
STANDARD OF CAREDopamine agonists
RESISTANCE MECHANISMDopamine pathway gene expression is altered
WHAT WE NORMALIZEDopamine pathway gene expression is normalized
ONE PLATFORM
Different targets, different peptides — one method: identify the dysregulated gene expression behind treatment resistance, then normalize it to restore the efficacy of the standard of care. Both programs are supported by AecorBio preclinical data.
The team
Leadership Team
Deep expertise across drug discovery, oncology, clinical development and early-phase trial design.
Dr. Bomi Framroze
Ph.D. · CEO & Co-Founder
33+ years in health sciences & biotech. Led discovery programs yielding 80+ patents. Prior C-level roles in oncology & immunology.
Prof. Karl Sylvester, MD
Head of Clinical Development
Directs clinical development and Phase 1b design. Surgeon-scientist with 20+ years in pediatric surgery & translational science at Stanford.
Prof. Sandy Srinivas, MD
Stanford School of Medicine, Professor of Medicine (Oncology)
Phase 1b Principal Investigator. Leading expert in genitourinary cancers and early-phase clinical trials in prostate cancer.
Robert Morgan
MS, JD · Head of Regulatory (Consulting)
35 years global regulatory experience focusing on innovative treatments across multiple therapeutic areas.
Prof. Stephen Sonis, MD
Senior Advisor
300+ publications, cited 35,000+ times. Harvard & Dana-Farber Cancer Institute.
Dr. Crawford Currie
MD, MBA · Medical Advisor
20+ years across clinical practice, pharma & finance. NHS surgeon, oncology lead. MBA Cranfield.
Partner with AecorBio Inc.
We are interested in co-development partnerships and investors aligned with our programs and IND timelines.
Email us at info@aecorbio.com to learn more
FORWARD-LOOKING STATEMENTS
This website contains forward-looking statements, including statements regarding AecorBio’s product candidates, their potential mechanisms and benefits, and planned preclinical, clinical, manufacturing and regulatory activities and timelines. These statements reflect current expectations and are subject to risks and uncertainties; actual results may differ materially. Preclinical results are not necessarily predictive of results in clinical studies. Our lead drug product and AecorBio’s other candidates are investigational and have not been approved by the U.S. Food and Drug Administration or any other regulatory authority for any use. AecorBio undertakes no obligation to update these statements except as required by law.
NO OFFER OF SECURITIES
This website is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offering of securities will be made only to qualified investors through definitive offering documents.